Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
NCT05776069
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Von Willebrand Diseases
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 12 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Vega Therapeutics, Inc
- Last updated on ClinicalTrials.gov
- August 26, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Orthopedic Institute for Children (UCLA) · Los Angeles, CA
- UC Davis Medical Center · Sacramento, CA
Colorado · 1
- University of Colorado School of Medicine · Aurora, CO
Georgia · 1
- Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory · Atlanta, GA
North Carolina · 1
- Science 37, Inc. · Morrisville, NC
Pennsylvania · 1
- Hemophilia Center of Western PA · Pittsburgh, PA
Tennessee · 1
- Vanderbilt University Medical Center · Nashville, TN
Texas · 1
- University of Texas Southwestern · Dallas, TX
Washington · 1
- Washington Center for Bleeding Disorders · Seattle, WA
Wisconsin · 1
- Versiti Comprehensive Center for Bleeding Disorders · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.